Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages 80-89

  Daniels, Gilbert H ^a   Vladic, Anton ^b   Brinar, Vesna ^c   Zavalishin, Igor ^d   Valente, William ^e   Oyuela, Pedro ^f   Palmer, Jeffrey ^f   Margolin, David H ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b University Hospital Sveti Duh   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; IMMUNOGLOBULIN; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN BINDING INHIBITORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENDOCRINOLOGIST; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SUBACUTE THYROIDITIS; THYROID DISEASE; THYROID FUNCTION TEST;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; THYROID DISEASES; THYROID FUNCTION TESTS; YOUNG ADULT;

EID: 84892156601     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2201     Document Type: Article

References (27)

1. Barbesino G. Drugs affecting thyroid function. Thyroid. 2010;20:763-770.
2. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354:1691-1695.
3. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253:98-108.
4. CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon α-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-1801.
5. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon α-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78:1069-1078.
6. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23:793-800.
7. Moore KL, Boscardin WJ, Steinman MA, Schwartz JB. Age and sex variation in prevalence of chronic medical conditions in older residents of US nursing homes. J Am Geriatr Soc. 2012;60:756-764.
8. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferonα-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011;10:338-348.
9. Akeno N, Smith EP, Stefan M, et al. IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol. 2011;186:4693-4706.
10. Ward DL, Bing-You RG. Autoimmune thyroid dysfunction induced by interferon-α treatment for chronic hepatitis C: screening and monitoring recommendations. Endocr Pract. 2001;7:52-58.
11. Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:693-702.
12. Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000;85:4254-4257.
13. Gillard P, Huurman V, Van der Auwera B, et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care. 2009;32:1817-1819.
14. Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist. 2008;13:167-174.
15. Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant. 2006;6:1084-1085.
16. Marrie RA, Yu BN, Leung S, et al. The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data. Neuroepidemiology. 2012;39:135-142.
17. McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid. 2013;23:14-24.
18. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P. Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab. 1988;67:656-662.
19. Wood LC, Ingbar SH. Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents. J Clin Invest. 1979;64:1429-1436.
20. Chung HK, Kim WB, Park DJ, Kohn LD, Tahara K, Cho BY. Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies. Thyroid. 1999;9:393-399.
21. Tamai H, Hirota Y, Kasagi K, et al. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment. J Clin Endocrinol Metab. 1987;64:718-722.
22. Tamai H, Kasagi K, Takaichi Y, et al. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab. 1989;69:49-53.
23. Arikawa K, Ichikawa Y, Yoshida T, et al. Blocking type antithyrotropin receptor antibody in patients with nongoitrous hypothyroidism: its incidence and characteristics of action. J Clin Endocrinol Metab. 1985;60:953-959.
24. Rees Smith B, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocr Rev. 1988;9:106-121.
25. Tamaki H, Amino N, Kimura M, Hidaka Y, Takeoka K, Miyai K. Low prevalence of thyrotropin receptor antibody in primary hypothyroidism in Japan. J Clin Endocrinol Metab. 1990;71:1382-1386.
26. Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118:6299-6305.
27. Meyer D, Coles, AJ, Oyuela, P, Purvis, A, Margolin, DH. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2013;2:60-63.